Pros and cons for systemic therapy in recurrent ovarian cancer

Anticancer Research

Volumn 29, Issue 7, 2009, Pages 2831-2836

  Oskay Özcelik, Gülten ^a   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chemotherapy; Hormonal therapy; Recurrent ovarian cancer; Treatment free interval

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LEUPRORELIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN; TREOSULFAN;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TOLERABILITY; EDEMA; FEMALE; HAND FOOT SYNDROME; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; LEUKOPENIA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RECURRENT CANCER; STRUCTURED QUESTIONNAIRE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECURRENCE;

EID: 69249177163     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA; Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C and Willemse PH: Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 10(Suppl): 87-92, 1999.
2. Lichtenegger W, Sehouli J and Buchmann E: Operative results after primary and secondary debulking-operations in advanced ovarian cancer. J Obstet Gyn Res 24(6): 447-451, 1998. (Pubitemid 29052050)
3. Oskay-Özcelik G, Lehmacher W, Könsgen D, Christ H, Kaufmann M, Lichtenegger W, Bamberg M, Wallwiener D, Overkamp F, Diedrich K, von Minckwitz G, Höffken K, Seeber S, Mirz R and J Sehouli: Breast cancer patients' expectations in respect ofthe physician-patient relationship and treatment management results of a survey of 617 patients. Ann Oncol 18: 479-484, 2007. (Pubitemid 46359626)
4. Oskay-Özcelik G: NOGGO International Satellite Session: Current controversies in the management of gynecologic cancers: focus on ovarian cancer: European survey: expression II perceptions and expectations on clinical management of ovarian cancer; ESGO 2007, Berlin.
5. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9(3): 389-393, 1991.
6. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A and Tropé C: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361(9375): 2099-2106, 2003.
7. du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Ulbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W and Jacobus Pfisterer: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329, 2003.
8. Pignata S, De Placido S, Biamonte R, Scambia G, Di Vagno G, Colucci G, Febbraro A, Marinaccio M, Lombardi AL, Manzione L, Cartenì G, Nardi M, Danese S, Valerio MR, de Matteis A, Massidda B, Gasparini G, Di Maio M, Pisano C and Perrone F: Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 6: 5, 2006. (Pubitemid 43085338)
9. Pfisterer J, Plante M, Vergote I et al: Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum-sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol 33: 12-16, 2003.
10. Du Bois A, Lück HJ and Bauknecht T: Second-line chemotherapy after platinum or platinum and paclitaxel-based chemotherapy for ovarian cancer: A systematic Review: German J Obst Gynecol 2000. (Pubitemid 30084181)
11. Markman M and Bookman MA: Second-line treatment of ovarian cancer. Oncologist 5: 26-35, 2000.
12. Conte PF, Gadducci A and Cianci C: Second-line treatment and consolidation therapies in advanced ovarian cancer. Int J Gynecol Cancer 11(S1): 52-56, 2001. (Pubitemid 32751386)
13. Sehouli J, Stengel D, Oskay-Özcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E and Lichtenegger W: Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: Results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26: 3176-3182, 2008.
14. Meier W, duBois A, Reuss A, Kuhn W, Gropp M, Pfisterer J, Kimmig R, Olbricht S, Wagner U, Richter B and Moebus V: Topotecan versus Treosulfan in early recurrent ovarian cancer after primary Platinum/Paclitaxel chemotherapy. A prospective randomized Phase III Trial of the AGO Ovarian Cancer Study Group. Int J Gynecol Cancer 14(Suppl. 1): 1-249, 2004.
15. Gore M, ten Bokkel Huinik W, Carmichael J, Gordon A, Davidson N, Coleman R Spaczynski M, Héron JF, Bolis G, Malmström H, Malfetano J, Scarabelli C, Vennin P, Ross G, and Fields SZ: Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 19(7): 1893-1900, 2001.
16. Von Hoff DD, Burris HA and Eckhardt J: Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 34(Suppl): 41-45, 1994.
17. Ten Bokkel Huinik W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC and Heron JF: Topotecan versus palictaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15: 2183-2193, 1997. (Pubitemid 27251118)
18. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME and Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14): 3312-3322, 2001. (Pubitemid 32642183)
19. Levy T, Inbar M, Menczer J, Grisaru D, Glezerman M and Safra T: Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian Gynecol Oncol 95: 686-690, 2004.
20. Morris R, Alvarez D, Andrews S, Malone J, Bryant C and Munkarah A: Topotecan weekly bolus chemotherapy for potentially chemosensitive relapsed ovarian cancer and peritoneal cancer - an update. Proc Am Soc Clin Oncol 22: 1846, 2003.
21. Sehouli J, Oskay-Oezcelik G, Stengel D, du Bois A, Markmann S, Loibl S, Wilke J, Nugent A, Belau A and Lichtenegger W: Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO). J Clin Oncol 25(18S): 5526, 2007.
22. Sehouli J, Oskay-Özcelik G, Kühne J, Stengel D, Hindenburg HJ, Klare P, Heinrich G, Schmalfeldt B, Mertens H, Camara O, Lichtenegger W and Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO): Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol 17: 957-961, 2006.
23. Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Klare P, Schmalfeldt B, Lichtenegger W, Chekerov R, Al-Batran SE, Neumann U and Sehouli J; Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO): Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multicenter phase II study of the NOGGO. Anticancer Res 28(2B): 1329-1334, 2008.
24. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D and Scambia G: Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26: 890-896, 2008.
25. Williams CJ: Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 1: CD001034, 2001.
26. du Bois A , Meier W, Lück HJ, Emons G, Moebus V, Schroeder W, Costa S, Bauknecht T, Olbricht S, Jackisch C, Richter B and Wagner U: Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 13(2): 251-257, 2002.
27. Kristensen G, Kaern J, Baekelandt M, Skeie-Jensensen T, dePont Christensen R, Åvall-Lundqvist E, Bergdahl M, Sandvei R, Hoegberg T and Grenmann S: Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer.: A NSGO study. J Clin Oncol 26(15S): 5508, 2008.